Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Deeper Dive: A Plethora of Prediction Models

Study Provides Insights That May Inform Prevention, Management of Mesothelioma

IASLC Releases Position Statement on Air Pollution on Earth Day

IASLC Responds to Call for Evidence

Researcher Reveals How Air Pollution May Cause Lung Cancer

Smoking Cessation in Lung Cancer Screening: The Latest Randomized Controlled Trial Evidence